Back to Directory
Survodutide
Metabolic & Weight ManagementGLP-1/Glucagon dual agonist showing exceptional results for weight loss and NASH.
Key Benefits
- ✓Impressive weight loss (15-19%)
- ✓Reduces liver fat dramatically
- ✓Treats NASH
- ✓Weekly dosing
- ✓Dual mechanism benefits
Dosing Information
Dosage Range
Under investigation
Frequency
Weekly
Typical Duration
Phase 3 trials ongoing
Detailed Protocol
Under clinical investigation. Administered via subcutaneous injection once weekly. Phase 3 trials ongoing.
About Survodutide
Survodutide (BI 456906) is a GLP-1/glucagon receptor dual agonist being developed by Boehringer Ingelheim and Eli Lilly. Phase 2 trials showed impressive weight loss (up to 19%) and NASH improvements. Weekly dosing.
Research Notes
Phase 2 trials showed 18.7% weight loss at highest dose and up to 80% reduction in liver fat. Phase 3 SYNCHRONIZE trials ongoing. Promising dual agonist candidate.
Potential Side Effects
- •Nausea and vomiting
- •Diarrhea
- •Generally manageable
- •Investigational
Always consult with a healthcare professional before starting any peptide therapy.